We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Looking for Value? Why It Might Be Time to Try Nucor (NUE)
Read MoreHide Full Article
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Nucor Corporation (NUE - Free Report) .
Nucor in Focus
NUE may be an interesting play thanks to its forward PE of 11, its P/S ratio of 1, and its decent dividend yield of 2.5%. These factors suggest that Nucor is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that NUE has decent revenue metrics to back up its earnings.
But before you think that Nucor is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 11.5% in the past 30 days, thanks to four upward revisions in the past one month compared to none lower.
So really, Nucor is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Image: Bigstock
Looking for Value? Why It Might Be Time to Try Nucor (NUE)
Value investing is always a very popular strategy, and for good reason. After all, who doesn’t want to find stocks that have low PEs, solid outlooks, and decent dividends?
Fortunately for investors looking for this combination, we have identified a strong candidate which may be an impressive value; Nucor Corporation (NUE - Free Report) .
Nucor in Focus
NUE may be an interesting play thanks to its forward PE of 11, its P/S ratio of 1, and its decent dividend yield of 2.5%. These factors suggest that Nucor is a pretty good value pick, as investors have to pay a relatively low level for each dollar of earnings, and that NUE has decent revenue metrics to back up its earnings.
Nucor Corporation PE Ratio (TTM)
Nucor Corporation PE Ratio (TTM) | Nucor Corporation Quote
But before you think that Nucor is just a pure value play, it is important to note that it has been seeing solid activity on the earnings estimate front as well. For current year earnings, the consensus has gone up by 11.5% in the past 30 days, thanks to four upward revisions in the past one month compared to none lower.
This estimate strength is actually enough to push NUE to a Zacks Rank #1 (Strong Buy), suggesting it is poised to outperform. You can see the complete list of today’s Zacks #1 Rank stocks here.
So really, Nucor is looking great from a number of angles thanks to its PE below 20, a P/S ratio below one, and a strong Zacks Rank, meaning that this company could be a great choice for value investors at this time.
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>